Contrary Capital announces closing of first fund


Nephrogen's investor, Contrary Capital, announced the closing of their Fund I, a $2.2M fund. 

Nephrogen stands out as a "Top 3 Startup" in the Cardinal Ventures Winter 2018 accelerator program


This winter, Nephrogen took part in Stanford's Cardinal Ventures Demo Day where 14 startups pitched their products to over 100 venture capital firms. Nephrogen was one of 3 startups to stand out of the crowd, with its at-home blood-testing platform and razor-like business model, many were intrigued by Nephrogen's vision for the future of healthcare. 

Nephrogen featured in Business Insider


Business Insider covered Stanford's Cardinal Ventures Demo Day and briefly spoke with Nephrogen's CEO, Demetri Maxim. 

Nephrogen accepted to Lightspeed Fellowship


Nephrogen will participate in Lightspeed's Summer 2018 fellowship program. Lightspeed's office is located in Menlo Park, CA where Nephrogen will be working this summer.

Nephrogen is accepted to StartX and participates in Spring 2017 accelerator program


Nephrogen participated in this spring's session of the accelerator program at StartX. We learned a lot during the session and are excited to join the StartX and StartX Med communities.


Corporate Headquarters move to Palo Alto


Nephrogen is happy to announce that we have officially moved our corporate headquarters to Palo Alto, California! All corporate and R&D work will be performed at our new headquarters, and we are very excited to take advantage of the amazing opportunities available to us in Silicon Valley.


Nephrogen's first patent is published


Nephrogen's first patent application was published online today with CEO Demetri Maxim as the sole inventor. It details a device currently in the pipeline that provides a simple, rapid, inexpensive, and minimally invasive method for detecting blood biomarkers of various life threatening diseases. This technology and underlying IP is currently being applied by Nephrogen to provide novel medical devices that aid in the early detection of chronic kidney transplant rejection. Check out the full patent here.